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&p.1:Abstract Breast and ovarian carcinomas share a region
of allelic loss on chromosome 17q25, suggesting that
these tumours may arise by similar molecular pathways.
We analysed paraffin-embedded tissues from 84 sporadic
ovarian carcinomas and 42 sporadic infiltrating ductal
carcinomas of the breast for abnormalities on chromo-
some 17. Loss of heterozygosity (LOH) of at least one
informative marker on 17q was identified in 49 of 82
(60%) ovarian carcinomas, as against only 6 of 40 (15%)
informative breast carcinomas (P<0.0001). In ovarian
carcinoma, LOH was most commonly observed for GH
on 17q23 (56%), and was also frequently observed at
17q21 (46%). In contrast, LOH of D17S1330/CTT16 on
17q25 was observed in only 19% of ovarian tumours.
LOH in breast carcinomas was most frequently observed
at 17q21 (16%), less frequently at 17q23 (7%) and not
identified at all at 17q25 in any breast cancers. Immuno-
histochemical analysis demonstrated overexpression of
the p53gene product in 38 of 84 (45%) ovarian carcino-
mas, as against 10 of 42 (24%) breast carcinomas
(P=0.0195). p53 immunoreactivity was significantly as-
sociated with LOH in ovarian and breast cancers. Immu-
nohistochemical expression of HER2/neu was observed
in 6 of 84 (7%) ovarian and 3 of 42 (7%) breast carcino-
mas. There was no relationship between HER2/neu im-
munoreactivity and LOH. Although sporadic carcinomas
of breast and ovary share some regions of allelic loss on
chromosome 17q, differences in other alterations on this
chromosome suggest divergent pathways of tumour de-
velopment.
&kwd:Key words Ovary · Breast · Carcinoma ·
Loss of heterozygosity · Chromosome 17&bdy:
Introduction
Chromosome 17 is one of the most frequent targets of
genetic damage in human neoplasia [25]. In particular,
three genes on chromosome 17 have been linked to the
development of breast cancer: p53, BRCA1 and
HER2/neu. Analyses of breast cancers have implicated
a ditional genes with tumour suppressor function. Stud-
ies of allelic loss using loss of heterozygosity (LOH) of
polymorphic genetic markers on chromosome 17 have
implicated the existence of one or more additional tu-
mour suppressor genes on the long arm of chromosome
17 distal to BRCA1[6, 17, 23, 29]. As further evidence
of this, a BRCA1-deficient chromosome 17 has been
shown to suppress tumorigenicity when transfected into
a p53-positive breast cancer cell line [28].
Recently, deletion mapping of microsatellite markers
was used to define a 3-cM region on 17q25, distal to the
genetic marker D17S1330, containing a putative tumour
suppressor gene inactivated in carcinoma of the breast
[16]. This region of 17q25 allelic loss has recently been
shown to be shared with ovarian carcinomas [15]. Other
alterations of chromosome 17 have also been associated
with both breast and ovarian cancer, including germline
mutations in the BRCA1gene [12, 21] and other regions
of LOH [1, 23].
We have undertaken a comparative study of 84 spo-
radic ovarian and 42 sporadic breast carcinomas to com-
pare alterations of chromosome 17 between these tu-
mours. We have analysed allelic loss in three regions of
17q proximal to the area of 17q25 (flanked by D17S722
and D17S802) already shown to contain a putative tu-
mour suppressor gene [15]. In addition, we used immu-
nohistochemistry to analyse the expression of p53 and
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HER2/neu (located on 17p13 and 17q12, respectively),
which have both been shown to be involved in the devel-
opment of breast [5, 27] and ovarian [9, 24] cancer.
Methods
Based on review of haematoxylin and eosin-stained slides and
availability of formalin-fixed, paraffin-embedded tissue, 84 inva-
sive ovarian adenocarcinomas and 42 infiltrating ductal carcino-
mas of the breast were identified with confluent areas of neoplasm
(at least 80% by visual examination). The histological subtypes of
the ovarian carcinomas were papillary serous (26), endometrioid
(28), mucinous (4), clear cell (14) and others (12: transitional cell
carcinomas, carcinosarcomas, and tumors of mixed histological
patterns). Anonymized tissue specimens were used in accordance
with informed consent provided by each patient at the time of sur-
gery, as approved by the institution’s Internal Review Board. Two
paraffin tissue blocks, one each of neoplastic and nonneoplastic
tissue, were selected from each case. DNA was extracted from
paraffin sections as previously described [10] and digested over-
night in 100 µl of 50 mmol/l TRIS pH 8.3 with 200 ng/µl protein-
ase K at 37°C. Samples were then boiled for 8 min, cooled on ice,
and spun for 5 min to pellet the debris. DNA extraction was per-
formed in batches with a reagent-only negative control.
LOH of genetic markers on chromosome 17q was identified
using primers designed to analyse five informative repeat sequenc-
es on chromosome 17q (Table 1): D17S855 and D17S1323 (dinu-
cleotide microsatellite markers intragenic to BRCA1 on 17q21,
GenBank U15595); EDH17B (a 12-bp insertion-deletion flanking
17beta-hydroxysteroid dehydrogenase on 17q21 near BRCA1
[11]); GH (a tetranucleotide repeat at the human growth hormone
locus on 17q23, GenBank J03071 [22]); and D17S1330/CTT16 (a
trinucleotide repeat on 17q25, GenBank G07947). All of these
markers are proximal to the defined area of interstitial deletion on
17q25 flanked by markers D17S722 and D17S802 [15].
PCR was performed with an initial denaturation step of 4 min
at 94°C coupled to 35 cycles of 1 min at 94°C, 2 min at the prim-
er-specific annealing temperature (Table 1), and 2 min at 72°C,
followed by a 7-min completion step at 72°C. Ten microlitres of
PCR product were loaded in parallel onto 8% neutral polyacryla-
mide and 3% agarose gels (1.5% NuSieve, FMC Bioproducts,
Rockland, Me. and 1.5% agarose, Gibco-BRL, Grand Island,
N.Y.) with 10 µl of 1×TBE buffer and 3 µl of loading dye. The
gels were stained in 0.5 µg/ml ethidium bromide and photo-
graphed with a Polaroid camera using an ultraviolet light source.
Allelic loss in neoplastic tissue was determined visually as loss of
more than 50% of the intensity of one allele relative to the other in
neoplastic compared to non-neoplastic tissue.
Immunohistochemical analysis of p53 protein in ovarian tu-
mours was performed in conjunction with an earlier study [9]. Im-
munoreactivity for p53 protein was assessed using antibody
PAb1801 (Oncogene Science, Uniondale, N.Y.), a murine mono-
clonal antibody specific for a denaturation-resistant epitope be-
tween amino acids 32 and 79 of the human p53 protein [3]. Using
the same block of neoplastic tissue selected for PCR analysis, tis-
sue sections of 4 µm thickness were pretreated with microwaving
in 10 mM citrate buffer and incubated overnight at room tempera-
ture with the primary antibody at a 1:1000 dilution as previously
described [9]. Following 1 h of incubation with a 1:200 dilution of
biotinylated antimouse IgG (Vector mouse ABC kit, Burlingame,
Calif.), the tissues were incubated for 30 min at room temperature
with 1 µg/ml streptavidin-alkaline phosphatase (BRL Life technol-
ogies, Bethesda, Md.). The samples were then incubated in the
dark for 1 h with nitroblue tetrazolium and 5-bromo-4-chloro-3-
indolyl phosphate substrate (BRL) for chromogen development.
Tumours were considered to be positive in the presence of diffuse
staining (confluent areas of tumour in which at least half of the
nuclei stained as estimated by visual examination).
Immunohistochemical analysis of HER2/neuamplification was
performed using the monoclonal antibody clone TAB-250 (mAb1,
Triton Laboratories, Alameda, Calif.), which recognizes an epi-
tope on the external domain of the HER2/neu gene product. De-
paraffinized tissue sections were sequentially incubated for 20 min
with 1.5% H2O2 in methanol (to quench endogenous peroxidase
activity) and for 10 min in 20% normal horse (“suppressor”) se-
rum. Following overnight incubation at room temperature with
primary antibody at a concentration of 1:50, the slides were incu-
bated sequentially with secondary biotinylated (horse anti-mouse)
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Table 1 Loci used for analysis of allelic loss on chromosome 17q in carcinomas of the ovary and of the breast&/tbl.c:&tbl.b:
Locus Location of Primer Sequence Annealing Approximate 
microsatellite temperature size (bp)
marker (°C)
EDH17B (17 beta- 17q21 5′-GCAAAGACGGGGTCTCATTCT-3′ 55° 255
hydroxysteroid dehydrogenase) 5′-AGAAGGTGAAGAACTCATCCA-3′
D17S855 (BRCA1) 17q21 5′-ACACAGACTTGTCCTACTGCC-3′ 57° 150
5′-GGATGGCCTTTTAGAAAGTGG-3′
D17S1323 (BRCA1) 17q21 5′-TAGGAGATGGATTATTGGTG-3′ 55° 155
5′-AAGCAACTTTGCAATGAGTG-3′
GH (growth hormone) 17q23 5′-TCCAGCCTCGGAGACAGAAT-3′ 54° 243
5′-AGTCCTTTCTCCAGAGCAGGT-3′
D17S1330 (CTT16) 17q25 5′-TGGCTAGTGGACAAAGTGGT-3′ 51° 174
5′-GGGAACAAATAATGAACAAAA-3 ′
&/tbl.b:
Table 2 Allelic loss on 17q in carcinoma of ovary and of breast&/tbl.c:&tbl.b:
LOH of any LOH of 17q21 LOH of 17q23 LOH of 17q25 LOH of 17q21 LOH of 
17q markera (17HSD, D17S855, (GH) (D17S1330/ onlyb 17q23–25 only
D17S1323) CTT16) 25 onlyb
Ovarian carcinoma 49/82 (60%) 33/72 (46%) 29/52 (56%) 11/57 (19%) 10/65 (15%) 10/65 (15%)
Breast carcinoma 6/40 (15%) 5/32 (16%) 2/27 (7%) 0/30 (0%) 3/29 (10%) 1/29 (3%)
a Of tumours informative for any of the analysed markers on chromosome 17q 
b Of tumours informative for markers on 17q21 andeither 17q23 or 17q25&/tbl.b:
antibody, avidin–biotin complex reagent (ABC Elite kit, Vector
Laboratory Systems, Burlingame, Calif.) and chromogen reaction
solution [3,3′-diaminobenzidine tetrahydrochloride (Sigma, St.
Louis, Mo.) in 0.04% H2O2]. Tumours were not considered posi-
tive unless confluent tumour cells demonstrated intense, discrete
staining of the cytoplasmic membrane.
Statistical analysis (Chi-square except where noted) was per-
formed using Statview vers. 4.01 (Abacus Concepts, Berkeley, Ca-
lif.).
Results
As summarized in Table 2, loss of at least one informa-
tive marker on 17q was identified in 49 of 82 (60%)
ovarian carcinomas, as against only 6 of 40 (15%) infor-
mative breast carcinomas (P<0.0001). Allelic loss of any
informative markers at 17q21 was always accompanied
by LOH of others at this locus. In ovarian carcinoma,
LOH was most commonly observed for GH on 17q23
(56%), and was also frequently observed at 17q21
(46%). LOH of D17S1330/CTT16 on 17q25 was ob-
served in only 19% of ovarian tumours. When histologi-
cal subtypes of ovarian cancers were analysed separately
(Table 3), there was very similar prevalence of LOH
among papillary serous and endometrioid carcinomas,
but much less LOH of 17q in clear cell carcinomas and
none at all in any of four mucinous carcinomas. LOH in
breast carcinomas was most frequently observed at
17q21 (16%), less frequently observed at 17q23 (7%),
and not identified at all at 17q25 in any breast cancers.
Examples of LOH are illustrated in Fig. 1.
LOH confined to informative markers on 17q21 (with
retention of heterozygosity of more distal markers) was
present in 3/29 (10%) breast carcinomas and 10/65
(15%) ovarian carcinomas. Conversely, allelic loss con-
fined to distal 17q (i.e., LOH of 17q23 or 17q25 with re-
tention of heterozygosity of 17q21) was observed in 1/29
(3%) breast cancers, as opposed to 10/65 (15%) ovarian
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Table 3 Allelic loss on 17q and immunohistochemical expression of p53and HER2/neuin histological subtypes of ovarian carcinoma&/tbl.c:&tbl.b:
Histological LOH of LOH of LOH LOH LOH of LOH of p53gene HER2/neu
subtype any17q 17q21 of 17q23 of 17q25 17q21 17q23–25 product gene product
of ovarian markera (17HSD, (GH) (D17S1330/ onlyb onlyb
carcinoma D17S855, CTT16)
D17S1323)
Papillary serous 16/25 12/22 8/13 4/20 6/21 2/21 16/26 0/26
(64%) (55%) (62%) (20%) (29%) (15%) (61%) (0%)
Endometrioid 20/27 13/23 13/17 3/17 3/20 5/20 14/28 1/28
(74%) (57%) (68%) (18%) (15%) (25%) (50%) (4%)
Mucinous 0/4 0/4 0/4 0/4 0/4 0/4 1/4 3/4
(0%) (0%) (0%) (0%) (0%) (0%) (25%) (75%)
Clear cell 6/14 2/12 3/10 1/8 1/10 2/10 2/14 0/14
(43%) (17%) (30%) (13%) (10%) (20%) (14%) (0%)
Otherc 7/12 6/11 5/8 3/8 0/10 1/10 5/12 2/12
(60%) (55%) (63%) (38%) (0%) (10%) (42%) (17%)
a Of tumors informative for any of the analyzed markers on chro-
mosome 17q
b Of tumours informative for markers on 17q21 and either 17q23
or 17q25
c Includes 2 mixed papillary serous-endometrioid carcinomas,
4 transitional cell carcinomas, 4 undifferentiated carcinomas and
2 carcinosarcomas&/tbl.b:
Fig. 1 Loss of heterozygosity on chromosome 17q in carcinomas
of the ovary and breast. Microsatellites were amplified from
paired samples of nonneoplastic tissue (N) and tumour (T). Infor-
mative tissues possessed two microsatellite alleles, indicated by
PCR products of slightly different sizes. Loss of heterozygosity
(LOH) was indicated by absence of one fewer of these two bands
in neoplastic than in nonneoplastic tissue, as shown for markers at
17q21 and 17q23 (arrows) in both the breast (left) and the ovarian
(right) carcinomas illustrated. LOH was more commonly seen in
carcinomas of the ovary than of the breast. Losses at 17q21 and
17q23 were more frequent than at 17q25 in both tumour types.
Breast tumours demonstrated LOH at 17q21 more frequently than
of 17q23, while the opposite was true for ovarian tumours&/fig.c:
carcinomas (P=0.0169). Three of 27 ovarian carcinomas
informative for markers on 17q21, q23 and q25 showed
LOH at all informative loci, indicating possible loss of
the entire chromosomal arm. None of 15 breast carcino-
mas informative at all loci showed widespread chromo-
somal loss.
The results of immunohistochemical analysis of the
p53 protein are illustrated in Fig. 2 and summarized in
Table 4. Diffuse nuclear accumulation of p53 protein, in-
dicating a missense mutation in the gene itself, was iden-
tified in 38 of 84 (45%) ovarian carcinomas, as against
10 of 42 (24%) breast carcinomas (P=0.0195) Immuno-
reactivity for p53 was more common in papillary serous
and endometrioid ovarian carcinomas than in clear cell
and mucinous tumours (Table 3). In cancers of the ovary
p53 immunoreactivity was associated with LOH on 17q:
29 of 36 (81%) p53-positive tumours demonstrated LOH
of at least one 17q marker, as opposed to 20 of 26 (43%)
p53-negative ovarian carcinomas (P=0.0007). A similar
correlation was observed in breast cancer: 4 of 9 (44%)
p53-positive breast carcinomas demonstrated LOH of at
least one 17q marker, as opposed to 2 of 31 (6%) p53-
negative breast carcinomas (P=0.0163, Fisher’s exact
test).
Immunohistochemical expression of HER2/neu was
observed in 6/84 (7%) ovarian and 3/42 (7%) breast car-
cinomas, as illustrated in Fig. 3 and summarized in Ta-
ble 4. Immunoreactivity was significantly more prevalent
among mucinous tumours of the ovary than papillary se-
rous, endometrioid and clear cell carcinomas. There was
no relationship between HER2/neu immunoreactivity
and LOH seen in ovarian or breast carcinomas.
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Fig. 2 Immunoreactivity for the p53 gene product in carcinomas
of breast and ovary. Diffuse nuclear staining results from accumu-
lation of p53 protein, indicative of a missense mutations in the p53
gene, as demonstrated in the carcinomas of breast (upper) and
ovary (lower) as illustrated above. Overexpression of the p53gene
product was significantly more frequent in carcinomas of the ova-
ry than of the breast. NBT-BCIP-stained immunochemical prepa-
rations&/fig.c:
Fig. 3 Immunoreactivity for the HER2/neugene product in carci-
nomas of breast and ovary. Tumours were considered to overex-
press the gene product if they demonstrated diffuse, strong decora-
tion of the cell membrane, as demonstrated in the illustrated exam-
ples of infiltrating carcinoma of the breast (upper) and mucinous
carcinoma of the ovary (lower). Immunohistochemical analysis
identified overexpression of HER2/neu in 7% of ovarian and
breast carcinomas. DAB-stained immunochemical preparations&/fig.c:
Table 4 Immunohistochemical expression of p53 and HER2/neu
in carcinoma of the ovary and of the breast&/tbl.c:&tbl.b:
p53gene product HER2/neugene product
Ovarian carcinoma 38/84 (45%) 6/84 (7%)
Breast carcinoma 10/42 (24%) 3/42 (7%)
&/tbl.b:
Discussion
As inherited mutations in BRCA1 predispose to both
breast and ovarian carcinoma, it was hoped that investi-
gation of this gene would increase our understanding of
the biological link between these malignancies. Studies
conducted before the discovery of BRCA1demonstrated
frequent LOH of 17q21 in sporadic breast [7] and ovari-
an [23] carcinomas, which was thought to indicate fre-
quent involvement of BRCA1 in the development of
these tumours. Subsequently, however, it was determined
that somatic mutations in BRCA1are substantially less
frequent in sporadic ovarian [20] and breast [12] cancers
than is LOH of 17q21. This is illustrated by the subgroup
analysed in this study previously analysed for mutations
in BRCA1[20]. All four tumours in the earlier study with
mutations in BRCA1demonstrated LOH of 17q21, but
15 other tumours with LOH of 17q21 lacked mutations
(including 5 tumours in which LOH was confined to
17q21). Other tumour suppressor genes on 17q21 have
been implicated in the development of breast and ovarian
carcinoma [1].
Patterns of allelic loss in ovarian [13, 14, 29] and
breast [6, 17] carcinoma suggest the presence of other
tumour suppressor genes on 17q, distal to 17q21, but the
genes involved may differ between these tumours. LOH
analysis of ovarian carcinomas indicates that GH on
17q23 is part of a minimum deletion unit on 17q [13,
14]. In contrast, studies of breast cancer have found that
loss of a region closer to the telomeric end was more
common than loss of GH itself [6, 17]. Our observation
of LOH of GH in 56% of ovarian cancers as opposed to
7% of breast cancers suggests that the presence of a tu-
mour suppressor gene near GH is more likely to be al-
tered in carcinomas of the ovary than of the breast.
A putative tumour suppressor gene elsewhere in 17q,
however, has been implicated in the development of spo-
radic carcinomas of both ovary and breast [6, 17, 29].
LOH of a 3-cM portion of 17q25 (distal to the marker
D17S1330 analysed in this study) was originally identi-
fied in breast cancers [16] and subsequently also in ovar-
ian carcinomas (using several of the ovarian tumours
analysed in this study) [15]. It thus appears likely that
while some genes on 17q may be important in the devel-
opment of both breast and ovarian cancer, others may be
significant principally in the development of one or the
other.
We found that a greater proportion of ovarian than of
breast cancers demonstrated immunoreactivity with the
p53 gene product. Immunohistochemical staining with
monoclonal antibody Pab1801 has been performed in
paraffin-embedded breast [5] and ovarian [18] carcinoma
and found to correlate well with p53missense mutations,
which comprise the majority of p53 mutations in human
neoplasia. Our finding of diffuse nuclear staining in 45%
of ovarian tumours as opposed to 24% of breast carcino-
mas is quite similar to the findings recorded in studies in
which frozen tissue sections of ovarian [19] and breast
[4] cancers were used.
In contrast to immunoreactivity for the p53gene prod-
uct, we saw no difference in HER2/neustaining between
ovarian and breast carcinomas. While amplification of
HER2/neu has been reported in up to 25–30% of breast
cancers [27], other studies have estimated that only 15%
of infiltrating ductal carcinomas demonstrate either am-
plification of the HER2/neugene [17] or overexpression
of its gene product [2]. Immunoreactivity with the
HER2/neuprotein was observed in 7% of the infiltrating
ductal carcinomas in this study. Some differences be-
tween studies may result from differences in methodolo-
gies. For this reason we utilized a monoclonal antibody
(TAB-250) that has been shown to be among the most
sensitive and specific in paraffin-embedded tissue for the
detection of HER2/neuoverexpression [26]. Furthermore,
because cytoplasmic staining has been shown to represent
cross-reactivity with a mitochondrial protein [8], we did
not count tumours as positive unless diffuse cells demon-
strated distinct and strong staining of the cell membrane.
In summary, studies have indicated that tumour sup-
pressor genes on 17q21 and 17q25 may be involved in
the development of sporadic carcinomas of both breast
and ovary. Despite these similarities, our data indicate
t at LOH on 17q and p53 protein immunoreactivity are
more common in ovarian carcinomas. Our data further
indicate the presence of a tumour suppressor gene in the
central portion of 17q that is more important in the de-
velopment of ovarian than of breast cancer.
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